NCT00466713

Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: —
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will investigate the effects of rosiglitazone, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. The primary purpose of the study is to determine whether treatment with an insulin-sensitizing medication will improve the heart's ability to metabolize glucose (sugar).

Detailed description

Nondiabetic patients with nonischemic cardiomyopathy who are insulin-resistance or insulin-sensitive based on a fasting homeostasis model assessment (HOMA) value are eligible for the trial. At baseline, a 6-minute walk test is performed, followed by assessment of coronary flow reserve with ammonia-PET imaging before/after adenosine infusion. Subjects are then given an oral glucose load (75g), followed by PET imaging with F-18-fluoro-2-deoxyglucose (FDG). Subjects then begin taking rosiglitazone 4 mg qd x 12 weeks, after which the 6-minute walk test \& PET imaging is repeated.

Conditions

• Dilated Cardiomyopathy

Interventions

Type	Name	Description
DRUG	Rosiglitazone therapy

Timeline

• Start date: 2007-03-01
• Primary completion: 2007-12-01
• Completion: 2007-12-01
• First posted: 2007-04-27
• Last updated: 2014-05-13

Locations

1 site across 1 country: United States